Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), constitutes the second leading cause of morbidity and mortality in patients with cancer besides the progression of cancer itself [1]. In addition, the incidence of cancer-associated VTE has increased over time mainly because of an improved prognosis of cancer, increased usage of anticancer-drugs with a potential higher risk of thrombosis, and increased detection by frequent imaging examinations for cancer assessment [2–4].
